110 related articles for article (PubMed ID: 16991089)
1. Fabry disease in mice protects against lethal disease caused by Shiga toxin-expressing enterohemorrhagic Escherichia coli.
Cilmi SA; Karalius BJ; Choy W; Smith RN; Butterton JR
J Infect Dis; 2006 Oct; 194(8):1135-40. PubMed ID: 16991089
[TBL] [Abstract][Full Text] [Related]
2. Oral therapeutic agents with highly clustered globotriose for treatment of Shiga toxigenic Escherichia coli infections.
Watanabe M; Matsuoka K; Kita E; Igai K; Higashi N; Miyagawa A; Watanabe T; Yanoshita R; Samejima Y; Terunuma D; Natori Y; Nishikawa K
J Infect Dis; 2004 Feb; 189(3):360-8. PubMed ID: 14745692
[TBL] [Abstract][Full Text] [Related]
3. Towards an attenuated enterohemorrhagic Escherichia coli O157:H7 vaccine characterized by a deleted ler gene and containing apathogenic Shiga toxins.
Liu J; Sun Y; Feng S; Zhu L; Guo X; Qi C
Vaccine; 2009 Oct; 27(43):5929-35. PubMed ID: 19682616
[TBL] [Abstract][Full Text] [Related]
4. Receptor affinity, stability and binding mode of Shiga toxins are determinants of toxicity.
Shimizu T; Sato T; Kawakami S; Ohta T; Noda M; Hamabata T
Microb Pathog; 2007; 43(2-3):88-95. PubMed ID: 17532600
[TBL] [Abstract][Full Text] [Related]
5. Oral administration of formaldehyde-killed recombinant bacteria expressing a mimic of the Shiga toxin receptor protects mice from fatal challenge with Shiga-toxigenic Escherichia coli.
Paton JC; Rogers TJ; Morona R; Paton AW
Infect Immun; 2001 Mar; 69(3):1389-93. PubMed ID: 11179303
[TBL] [Abstract][Full Text] [Related]
6. An in vitro model of Fabry disease.
Shu L; Murphy HS; Cooling L; Shayman JA
J Am Soc Nephrol; 2005 Sep; 16(9):2636-45. PubMed ID: 16033856
[TBL] [Abstract][Full Text] [Related]
7. Effect of Gb3 in lipid rafts in resistance to Shiga-like toxin of mutant Vero cells.
Hanashima T; Miyake M; Yahiro K; Iwamaru Y; Ando A; Morinaga N; Noda M
Microb Pathog; 2008 Aug; 45(2):124-33. PubMed ID: 18541402
[TBL] [Abstract][Full Text] [Related]
8. Pathogenic mechanism of mouse brain damage caused by oral infection with Shiga toxin-producing Escherichia coli O157:H7.
Kita E; Yunou Y; Kurioka T; Harada H; Yoshikawa S; Mikasa K; Higashi N
Infect Immun; 2000 Mar; 68(3):1207-14. PubMed ID: 10678928
[TBL] [Abstract][Full Text] [Related]
9. Bovine immune response to shiga-toxigenic Escherichia coli O157:H7.
Hoffman MA; Menge C; Casey TA; Laegreid W; Bosworth BT; Dean-Nystrom EA
Clin Vaccine Immunol; 2006 Dec; 13(12):1322-7. PubMed ID: 17050743
[TBL] [Abstract][Full Text] [Related]
10. The effect of probiotics and organic acids on Shiga-toxin 2 gene expression in enterohemorrhagic Escherichia coli O157:H7.
Carey CM; Kostrzynska M; Ojha S; Thompson S
J Microbiol Methods; 2008 May; 73(2):125-32. PubMed ID: 18328583
[TBL] [Abstract][Full Text] [Related]
11. The serine 31 residue of the B subunit of Shiga toxin 2 is essential for secretion in enterohemorrhagic Escherichia coli.
Shimizu T; Kawakami S; Sato T; Sasaki T; Higashide M; Hamabata T; Ohta T; Noda M
Infect Immun; 2007 May; 75(5):2189-200. PubMed ID: 17325057
[TBL] [Abstract][Full Text] [Related]
12. Assessment in mice of the therapeutic potential of tailored, multivalent Shiga toxin carbohydrate ligands.
Mulvey GL; Marcato P; Kitov PI; Sadowska J; Bundle DR; Armstrong GD
J Infect Dis; 2003 Feb; 187(4):640-9. PubMed ID: 12599081
[TBL] [Abstract][Full Text] [Related]
13. Prevalence, virulence profiles, and clinical significance of Shiga toxin-negative variants of enterohemorrhagic Escherichia coli O157 infection in humans.
Friedrich AW; Zhang W; Bielaszewska M; Mellmann A; Köck R; Fruth A; Tschäpe H; Karch H
Clin Infect Dis; 2007 Jul; 45(1):39-45. PubMed ID: 17554698
[TBL] [Abstract][Full Text] [Related]
14. Neurophysiological, behavioral and morphological abnormalities in the Fabry knockout mice.
Rodrigues LG; Ferraz MJ; Rodrigues D; Pais-Vieira M; Lima D; Brady RO; Sousa MM; Sá-Miranda MC
Neurobiol Dis; 2009 Jan; 33(1):48-56. PubMed ID: 18848893
[TBL] [Abstract][Full Text] [Related]
15. Quantitative determination of globotriaosylceramide by immunodetection of glycolipid-bound recombinant verotoxin B subunit.
Zeidner KM; Desnick RJ; Ioannou YA
Anal Biochem; 1999 Feb; 267(1):104-13. PubMed ID: 9918661
[TBL] [Abstract][Full Text] [Related]
16. Tissue and plasma globotriaosylsphingosine could be a biomarker for assessing enzyme replacement therapy for Fabry disease.
Togawa T; Kawashima I; Kodama T; Tsukimura T; Suzuki T; Fukushige T; Kanekura T; Sakuraba H
Biochem Biophys Res Commun; 2010 Sep; 399(4):716-20. PubMed ID: 20692233
[TBL] [Abstract][Full Text] [Related]
17. Prospects for preventing serious systemic toxemic complications of Shiga toxin-producing Escherichia coli infections using Shiga toxin receptor analogues.
Karmali MA
J Infect Dis; 2004 Feb; 189(3):355-9. PubMed ID: 14745691
[No Abstract] [Full Text] [Related]
18. Shiga toxin mode of action in E. coli O157:H7 disease.
Obrig TG
Front Biosci; 1997 Dec; 2():d635-42. PubMed ID: 9392626
[TBL] [Abstract][Full Text] [Related]
19. An easy and sensitive method for determination of globotriaosylceramide (Gb3) from urinary sediment: utility for Fabry disease diagnosis and treatment monitoring.
Rozenfeld PA; De Francesco NP; Borrajo GJ; Ceci R; Fossati CA
Clin Chim Acta; 2009 May; 403(1-2):194-7. PubMed ID: 19268437
[TBL] [Abstract][Full Text] [Related]
20. Characteristics of O157 versus non-O157 Shiga toxin-producing Escherichia coli infections in Minnesota, 2000-2006.
Hedican EB; Medus C; Besser JM; Juni BA; Koziol B; Taylor C; Smith KE
Clin Infect Dis; 2009 Aug; 49(3):358-64. PubMed ID: 19548834
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
